BioPharma Resources

Drug Trial Radar · NCT07860216

Phase III Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

Phase III Multicenter, Randomized, Blinded, Placebo-controlled Trial Assessing the Efficacy, Safety, and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged ≥60 Years

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 25,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

25,000

Planned (sponsor's estimate)

Start

Aug 21, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Beijing BeneWill Technology Development Co., LtdAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase III clinical trial with a multicenter, randomized, blinded, placebo-controlled design to evaluate the protective efficacy, safety, and immunogenicity of the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) in individuals aged 60 and above. Sample Size and Trial Grouping: This trial plans to enroll 25,000 trial participants aged ≥60 years (with approximately 30% aged 70 and above), with a relatively balanced gender distribution. Participants of each age group (60-69 years old, ≥70 years old) will be randomly assigned to the trial group and the placebo group in a 1:1 ratio. The sample size for the immunogenicity subgroup is not calculated based on statistical power. Referring to similar clinical trials of RSV vaccines and in conjunction with the immunogenicity observation objectives of this trial, the first 300 trial participants (including those from both age groups) from each site under the leading institution will be included in the immunogenicity subgroup, for a total of 1,200 participants.

Conditions

  • Assessing the Effectiveness of Vaccines in Preventing Adult RSV-caused Lower Respiratory Tract Disease (LRTD)

Interventions

  • Recombinant respiratory syncytial virus vaccine (CHO cell)Biological

    Test vaccine BW-201 (Adj 1): After mixing the "recombinant respiratory syncytial virus vaccine adjuvant injection" upside down, fully aspirate and inject it into the "RSV vaccine" lyophilized powder for re-dissolution. Slowly rotate the vial to mix, and use it after complete dissolution. After mixing the antigen and adjuvant, store them in a refrigerator at 2°C-8°C in the dark and use them within 4 hours. Before use, they need to be mixed again. If the mixture of antigen and adjuvant is left at room temperature (not exceeding 25°C), it needs to be used within 30 minutes. After mixing 1 bottle of adjuvant solution according to the above steps, aspirate the entire content and add it to the antigen, followed by mixing. Each person should receive 0.5mL per injection, administered intramuscularly into the deltoid muscle on the lateral side of the upper arm. Intravenous injection is strictly prohibited.

  • Sodium Chloride Injection 0.9%Biological

    The placebo is a 0.9% sodium chloride solution. Each person is to receive 0.5mL for intramuscular injection, with the injection site being the deltoid muscle on the lateral side of the upper arm. Intravenous injection is strictly prohibited. The remaining 0.9% sodium chloride solution (approximately 9.5mL) should be disposed of as waste.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The first-time incidence rate per person-year of Lower Respiratory Tract Disease (LRTD).Time frame: From 14 days after vaccination until the end of S1, the evaluation period can last up to 12 months.

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Guizhou Provincial Center for Disease Control and Prevention

    GuiZhou, Guizhou, China · Recruiting

  • Hebei Provincial Center for Disease Control and Prevention

    Hebei, Hebei, China · Recruiting

  • Hubei Provincial Center for Disease Control and Prevention

    HuBei, Hubei, China · Not yet recruiting

  • Hunan Province Center for Disease Control and Prevention

    HuNan, Hunan, China · Recruiting

  • Shandong Provincial Center for Disease Control and Prevention

    Shandong, Shandong, China · Not yet recruiting

  • Shaanxi Provincial Center for Disease Control and Prevention

    Shanxi, Shanxi, China · Not yet recruiting

  • Baoshan Second People's Hospital in Yunnan Province

    Baoshan, Yunnan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.